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ABSTRACT

Thyroid hormone regulates essential processes in brain development such as neural cell
migration, differentiation, signaling, and myelination, particularly during the early stages of
gestation. During this time, fetal thyroid hormone accessibility depends on the placental transfer
of thyroid hormones. Deficiency of thyroid hormone during fetal and postnatal periods may lead
to permanent mental retardation and neurological deficits. Clinical studies have been conducted
demonstrating links between maternal hypothyroidism and numerous neurodevelopmental
disorders such as Autism Spectrum Disorder (ASD), Attention Deficit Hyperactivity Disorder,
lower IQ, behavioral disorders, and psychiatric disorders. To investigate the effects of thyroid
hormone actions on perinatal brain development potentially present in ASD, a literature review
was conducted using PubMed, UCF EBSCOhost, and Google Scholar to obtain relevant papers
for analysis. Across the board, abnormal maternal thyroid function, especially suboptimal
maternal free thyroxine hormone, was associated with increased risk for neurological disorders,
including ASD. The implications of this study emphasize the importance of managing maternal
hypothyroidism during pregnancy to possibly reduce the incidence of neurodevelopmental
disorders such as ASD.
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INTRODUCTION

Autism Spectrum Disorder (ASD) is characterized by the Center for Disease Control and
Prevention (CDC) as a developmental disability resulting in varying levels of social,
communicative, and behavioral disorders (1). The prevalence of ASD has skyrocketed in recent
years, with estimates currently lying around 1 in 54 children affected with a ratio of
approximately 4:1 boys to girls (1). Signs and symptoms can include avoiding eye contact, not
looking at objects when someone points to them, repeating actions, appearing unaware when
being spoken to, and failing to show interest (1, 2). Diagnosis of ASD can occur as young as 18
months of age and with great reliability after two years of age (1). Current diagnostic criteria
from the DSM-V focus on deficits in social interaction, nonverbal communicative patterns, and
development and understanding of relationships (3).

Characteristics of ASD Brains
While the etiology of ASD remains unknown, numerous studies have highlighted
deviations in neuroanatomical structures pointing towards a developmental pathology. One study
of 277 ASD patient brains exhibiting deviation from neurotypical brains identified six areas of
the brain with converging information in magnetic resonance images (MRI) including the lateral
occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate
to the right parietal operculum (4). Multiple studies concur on the presence of abnormal
connectivity present in ASD brains as well as alterations in grey and white matter (5, 6). Areas
associated with social communication and repetitive behaviors such as the superior temporal
gyrus and cingulate cortex have shown dysfunctional activation in functional MRI studies (5).
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Potential early markers for ASD were suggested in a study analyzing the presymptomatic period
of approximately zero to two years of age, including cortical surface area growth, increased
volume of extra-axial cerebrospinal fluid, and abnormal white matter connectivity in the genu of
the corpus callosum (6). This study also identifies regions of the brain prominently associated
with the pathology of ASD, consistent with clinical presentation. These include the cerebellum,
which functions in higher cognitive processes and language, the amygdala, which plays a role in
emotional processing, and the frontal cortex that regulates numerous cognitive processes and
executive brain functions such as planning, social behavior, and communication (6). Multiple
studies confer that brain imaging within the first year of life could potentially lead to the
prediction of ASD before visible diagnostic symptoms arise (7).

Thyroid Hormones and Brain Development
Fetal brain development during gestation is heavily influenced by thyroid hormones
responsible for crucial functions such as neural cell migration, differentiation, and
synaptogenesis (8). Before midgestation, the mother is the only source of thyroxine (T4);
therefore, adequate concentrations of maternal serum T4 for placental transfer to the fetus is
essential for typical neurodevelopment (9). Maternal thyroid dysfunction is strongly associated
with poor outcomes for mother and child, such as pre-eclampsia, spontaneous abortion,
premature birth, low birth weight, neurological cretinism, and other neurological deficits in the
child (10, 11).
Given the implications of maternal thyroid hormone levels on fetal brain development,
dysfunction of the maternal thyroid could point to the emerging etiopathological identification of
impacted neurodevelopmental structures in ASD. The goal of this research is to conduct a
2

literature review on the association of maternal thyroid dysfunction with adverse neurological
outcomes in the fetus that is potentially linked to ASD diagnosis as well as impacts of treating
maternal thyroid disorders to reduce the risk of ASD.
Thyroid hormones thyroxine (T4) and 3,5,3’-triiodothyronine (T3) are crucial for the
development of many fetal structures, especially the central nervous system (8, 12). Upon
entering the brain, thyroid hormones act upon class II nuclear receptors to control the expression
of specific genes. These receptors act as a corepressor when there is no binding of the hormone,
but upon particular hormone binding, transcription is stimulated (12). In the brain, T3 binding to
thyroid nuclear receptor isoforms stimulates transcription of genes influencing processes,
including myelination, cell differentiation, signaling, and migration (8, 13). The specific genes
that thyroid hormone bind to include integrin ανβ3 membrane receptor that stimulates neocortex
expansion, the Reln gene that influences neuronal migration in the cerebral cortex, and the Shh
gene that controls granular cell proliferation (14). Any conflict in these processes can lead to
deficits in neuroontogenesis of various brain structures. For example, a study found that mutation
of thyroid hormone receptor beta isoform leads to impairment in development of the cerebellum
due to lack of granular cell proliferation and migration in the external granular layer (15). A
plethora of evidence of similar detrimental effects to other neuroanatomical structures and
functions as a result of varying levels of maternal thyroid hypofunction has been demonstrated
including the rate of neurogenesis (16), neocortical neuronal migration (17), cortical morphology
(18), spatial learning and synaptic nature (19), and hippocampus and memory (20). Furthermore,
studies have pinpointed the timing of specific impairments to correspond to the period of thyroid
hormone inadequacy during gestation (13, 21).
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Thyroid Physiology and Placental Transfer
Thyroid physiology is regulated by the hypothalamic-pituitary axis. Thyroid-releasing
hormone (TRH) is secreted by neurons in the hypothalamus and stimulates production of thyroid
stimulating hormone (TSH) in the anterior pituitary by activating thyrotroph cells (22). TSH
stimulates follicular cells of the thyroid to synthesize and release T3 and T4. T3 is the active
form of the thyroid hormone but is secreted in lower quantity (20%) compared to T4 (80%) (22).
Most T3 production results from conversion of T4 to T3 by deiodinases. In peripheral tissues like
the liver and kidneys, T3 is converted to T4 by type 1 deiodinase while in the brain this
conversion occurs via type 2 deiodinase produced by glial cells (23). Both T3 and T4 in high
levels can cause negative feedback on the anterior pituitary release of TSH, ultimately decreasing
stimulation of T3 and T4 production (22).
The fetus receives thyroid hormone after maternal T3 and T4 cross the placental barrier
during the first trimester. Research suggests that the blood-brain-barrier (BBB) is not permeable
to the T3 form of thyroid hormone; therefore, the source of T3 in the fetal brain is the conversion
of T4 to T3 after T4 crosses the BBB (12). Administering T4 maintains adequate physiological
levels of T3 in the brain (12).
Specific transporter proteins are required for thyroid hormones to cross plasma
membranes. Thyroxine-binding globulin (TBG), transthyretin (TTR), and albumin (HSA) are the
main serum proteins that bind thyroid hormone for transport (24). Transporter proteins for
placental transfer of thyroid hormones remain up for debate. TTR is synthesized and secreted by
placental trophoblast cells and could play a role in transport of T3 and T4 to fetus (25). Organic
anion-transporting polypeptide, L-type amino acid, and monocarboxylate transporter are other
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proteins identified that bind thyroid hormone for transport and are active in multiple cell types
within the placenta (26).

Thyroid Function During Pregnancy
When a woman becomes pregnant, there is a notable change in her thyroid physiology to
ensure adequate thyroid hormone for herself and the fetus. This change is crucial since the fetal
thyroid does not develop enough to produce thyroid hormone until approximately the 20th week
of gestation (10, 27). In a typical pregnancy, serum free T4 levels increase during the first and
second trimesters through a mechanism of increased thyroid hormone binding globulin
production in the liver due to higher estrogen levels, which increases synthesis of T3 and T4
(27). Serum human chorionic gonadotropin (hCG) glycoprotein is produced primarily in the first
trimester of pregnancy by the placenta. It acts as a weak agonist to TSH, further increasing T3
and T4 synthesis while simultaneously suppressing TSH level (27).
Thyroid dysfunction is relatively common in pregnancy with an estimated prevalence of
2-4% (11). Some risk factors for thyroid dysfunction include age greater than 30 years, type I
diabetes or other autoimmune disorder, multiple prior pregnancies, family history of thyroid
disease, and morbid obesity (28). It is important to identify the different classifications of thyroid
hypofunction in the context of this research. Overt hypothyroidism is characterized by low free
T4 and high TSH concentrations with a prevalence estimated to be between 0.2-1.0% (29).
Subclinical hypothyroidism has presence of standard free T4 with elevated TSH levels and
represents the most common type of thyroid dysfunction in pregnancy with estimates between
1.5-4.0% (30). Hypothyroxinemia is an isolated condition in pregnancy in which free T4 is
below the 2.5th percentile with a normal TSH concentration (31). Differentiating these three
5

classifications of thyroid hypofunction is essential when analyzing the effectiveness of
diagnostic techniques and possible medication suggestions.
Considering the importance of thyroid hormone levels for fetal nervous system
development discussed as well as the high prevalence of maternal thyroid hypofunction, the goal
of this research is to analyze the literature available to evaluate the potential benefits of universal
early maternal thyroid screening. This idea paired with subsequent medical intervention to
standardize maternal thyroid levels could possibly reduce the risk of adverse fetal outcomes such
as ASD.
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METHODS

•

To investigate effects of thyroid hormone actions on perinatal brain development
potentially present in ASD, a literature review was conducted using PubMed, UCF
EBSCOhost, and Google Scholar.

•

These databases were searched for articles pertaining to thyroid function on brain
development in ASD pregnancy by inputting keywords such as: Autism, thyroid function,
pregnancy, maternal, hypothyroidism, hypothyroxinemia, brain development,
levothyroxine.

•

Articles containing selected key words were analyzed and selected based on relevance.
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MATERNAL THYROID HYPOFUNCTION AND ASD DIAGNOSIS
RATES

Numerous case-cohort studies have been conducted analyzing maternal thyroid
hypofunctions of varying severity and subsequent diagnoses of neurological disorders in the
child, especially involving ASD.
Levie et al. conducted a meta-analysis to assess impacts of low maternal free T4 levels
during early pregnancy (less than 18 weeks) on IQ and autistic traits. They concluded that low
maternal free T4 was associated with lower verbal and nonverbal IQ across all cohorts,
hypothyroxinemia has a possible association with autistic traits, and confirmed the reliability of
free T4 as an indicator of the fetal thyroid state (32).
A case-cohort study assessed free T4 and thyrotropin level at week 9 of pregnancy and
subsequent diagnoses of neurodevelopmental disorders including seizures, ASD, and ADHD in
the children. Abnormal maternal thyroid function was most prevalent in the ASD cases
compared to the other disorders. Maternal overt hypothyroidism presented the most risk factors
for ASD (33). This research group produced a follow-up study that reassessed the
neuropsychological performance of the children at age five years and reaffirmed that maternal
thyroid dysfunction caused deficits in neurological development. Additionally, after performing
intelligence and function tests, the researchers were able to draw further conclusions that
maternal overt hypothyroidism had a greater effect on intelligence in the child while maternal
hypothyroxinemia mainly affected motor and executive functions as well as behavior problems
(34).
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A retrospective cohort study showed that women diagnosed with hypothyroidism both
before and during pregnancy had children with higher rates of ASD diagnosis. The association
was seen in ASD diagnosis in both boy and girl children (35). Fetene et al. conducted a
systematic review regarding maternal thyroid dysfunction and neurological disorders in the child
and concluded that particularly maternal overt hypothyroidism displayed the highest rates of
behavior and psychiatric disorders including ASD (36).

A Focus on Hypothyroxinemia
Another case-cohort study found an association between women with severe
hypothyroxinemia (free T4 < 5th percentile and normal TSH) and a four-fold increased risk of
having a child with probable ASD based on a Pervasive Developmental Problem subscale (37).
Thompson et al. conducted a large scale meta-analysis of 39 studies showing association of
maternal hypothyroxinemia and subclinical hypothyroidism with intellectual disabilities and
neurodevelopmental disorders in children (38).
A 3-year follow-up study after collection of maternal free T4 levels at 12 weeks of
gestation demonstrated that maternal hypothyroxinemia leads to a higher rate of deficits in
mental and motor function in children. This study also showed that an increase to standard levels
of free T4 in women with hypothyroxinemia in weeks 24-32 of gestation did not have better fetal
outcomes (39). This data reflects the crucial function of thyroid hormone in early gestation for
fetal brain development before the fetus is able to synthesize T3 and T4 independently.
Similarly, Kooistra et al. assessed neurobehavioral function of infants born to mothers with
maternal hypothyroxinemia at 12 weeks gestation. Neonates of women with low free T4 levels in
9

early pregnancy scored significantly lower on the Neonatal Behavior Assessment Scale which
assesses motor behavior, response to stress, adaptive behavior, and state organization at 3 weeks
of age. The results also established that only first-trimester maternal hypothyroxinemia acted as a
predicting factor for the assessment score, once more aligning with the timeline of fetal
neurodevelopment (40).
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CLINICAL INTERVENTIONS FOR MATERNAL THYROID
HYPOFUNCTION AND FETAL OUTCOMES

Considering the well-documented adverse maternal and fetal outcomes of various levels
of maternal thyroid hypofunction including pre-eclampsia, spontaneous abortion, premature
birth, low birth weight, neurological cretinism, and other neurological deficits (10, 11), clinical
interventions for affected women planning pregnancy is encouraged.
Treatment options for hypothyroidism primarily include synthetic hormone replacement.
Synthetic T4, levothyroxine (LT4), is the most common medication administered to patients with
low T4 levels (41). LT4 and liothyronine (synthetic T3) combination therapies have also been
developed; however, recent research confers that LT4 should remain standard of care for
suboptimal thyroid hormone levels including hypothyroxinemia as clinical studies have shown
inconclusive results that LT4-liothryonine combination therapies are superior to LT4
monotherapy (42, 43).
Duntas and Jonklaas identified factors that may require adjustment of a patient’s LT4
dose including weight and hormonal changes, aging, and pregnancy citing that up to 85% of
pregnant women require an increase of their LT4 dose (44). The 2017 Guidelines of the
American Thyroid Association for the Diagnosis and Management of Thyroid Disease During
Pregnancy and the Postpartum recommends LT4 treatment for women with overt
hypothyroidism and encourages consideration of LT4 treatment for women with subclinical
hypothyroidism to avoid possible progression of hypothyroidism upon becoming pregnant. The
guidelines emphasize monitoring of TSH levels every 4 weeks and encourage LT4 treatment
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when TSH is above 2.5 mU/L. It is recommended that women receiving LT4 treatment for
hypothyroidism increase their dose by 20-30% upon confirmation of pregnancy (45).

Case Studies: Levothyroxine Treatment During Pregnancy
Case studies analyzing maternal and fetal outcomes when the mother is treated with LT4
during pregnancy are in relative abundance. The Thyroid Hormone Early Adjustment in
Pregnancy (THERAPY) trial concluded that increasing LT4 dose by two tablets upon
confirmation of pregnancy successfully mirrors typical pregnancy physiology and reduces
hypothyroidism in the mother in the first trimester (46).
A 2019 meta-analysis conducted supports the benefits of LT4 medication in women with
subclinical hypothyroidism during pregnancy citing lower risk of miscarriage and preterm birth
(47). Meta-analyses of randomized controlled trials also show evidence for higher delivery rates
and lower miscarriage rates with LT4 supplementation during pregancy. These studies have also
demonstrated reduced gestational diabetes and hypertension in mothers, higher birth weights,
and fewer congenital malformations with LT4 intervention (48, 49).
One clinical study analyzed the effects of LT4 supplementation in pregnant women with
subclinical hypothyroidism compared to pregnant women with hypothyroxinemia. The
significant findings were reduced premature birth and low birth rate risks in both groups and
additionally decreased gestational hypertension in the subclinical hypothyroidism group (50).
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Clinical research regarding LT4 intervention for maternal hypofunction during pregnancy
and subsequent analysis of neurological outcomes in the fetus is few and far between. The results
tend to not support the hypothesis of this research.
Casey et al., found that women treated for subclinical hypothyroidism and
hypothyroxinemia at means of 16.7 and 17.8 weeks of gestation respectively did not have
children with significantly better neurocognitive outcomes than untreated women (51). Another
study analyzed randomized controlled trials and found lacking data for evidence of less risk for
neurosensory disability in the child after the mother was treated with LT4 for thyroid
hypofunction. One trial included women screened before 11 weeks gestation and the other trial
included women screened before 15 weeks gestation (52). A solo randomized control trial
analyzed children at 3 years of age and did not find improvement in cognitive function in
children born to mothers treated for hypothyroidism at 12 weeks 3 days median gestation (53).
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DISCUSSION

Implications

Gaps in the Research
While conducting this literature review, it became apparent that a gap in the research
exists in assessing the effectiveness of LT4 treatment for maternal hypofunction and subsequent
neurological outcomes, ASD traits, and ASD diagnosis of offspring. A multitude of studies
suggest that adverse maternal and fetal outcomes such as pre-eclampsia, gestational diabetes and
hypertension, early delivery, miscarriage, low birth weight, and congenital malformations are
reduced by adequate LT4 intervention (44-50). The few studies that do include assessment of
neurological outcomes in children only consider IQ scores as a comparison benchmark to the
control individuals (51-53). In order to better understand the possibility of reducing ASD in
children with LT4 treatment for hypothyroid mothers, researchers should conduct studies
including more in depth neurological follow-up including ASD diagnosis as well as evaluation of
ASD traits such as social, communicative, and behavioral deficits.

Timing of LT4 Treatment
A crucial factor to consider when analyzing the effects of LT4 intervention on neurological
outcomes is the gestational age of the embryo or fetus when the treatment begins. The mother is
the only source of thyroid hormone for the fetus up to midway through the pregnancy (9). Key
neurological structures and begin their development as early as week three of gestation
14

including: medulla, pons, cerebellum, thalamus, hypothalamus, amygdala, neocortex, and
hippocampus (50, 51). Additionally, essential brain functions synaptogenesis, myelinogenesis,
and gliogenesis occur in the fetus as early as week five (54, 55).
The current clinical studies analyzing the effect of LT4 treatment during pregnancy on
fetal neurodevelopmental outcomes show concerning gestational age for the start of the
treatments. The studies averaged a median gestation ranging from 12-18 weeks as the starting
point for implementation of thyroxine replacement (51-53). Other studies have demonstrated that
the specific time of insufficient thyroid hormone during gestation corresponds to deficits in the
typical development at the same point in time (13, 21). This creates questions about the efficacy
of LT4 supplementation on nervous system development after the first trimester.

Necessity for Universal Early Thyroid Screening

It is evident that adequate thyroid hormone levels are necessary to ensure a typical
development of numerous vital organs, especially in the central nervous system. For this reason,
debates on the application of universal thyroid screening has been an emerging topic in prenatal
care as well as for those trying to conceive. Current protocol used by most healthcare providers
only seeks to target pregnant women with overt hypothyroidism (56). An analysis of costeffectiveness of universal screening for subclinical hypothyroidism in pregnancy found that
universal screening of all pregnant women is cost-effective in both financial as well as quality of
life considerations (57). Taylor et al. highlight the importance to recruit women pre-conception
for clinical studies to further confirm the efficacy of immediate T4 replacement as necessary
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(53). For this reason, many researchers and clinicians are now urging the universality of thyroid
screening to prevent neurological malformations (58-60).
Universal thyroid screening could allow the execution of effective and timely treatment
for overt and subclinical levels of maternal thyroid hypofunction that could show promise in
ameliorating risk for adverse neurological outcomes in the fetus, especially the risk of ASD.
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